Enrolling by invitationNCT05332054
Long-Term Follow-up Study
Studying Acute myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Caribou Biosciences, Inc.
- Intervention
- Caribou-sponsored investigational therapy(biological)
- Enrollment
- 150 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2041
Study locations (30)
- University of Alabama, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Honor Health Research Institute, Scottsdale, Arizona, United States
- University of California Irvine, Irvine, California, United States
- University of California San Diego, La Jolla, California, United States
- University of Colorado, Denver, Colorado, United States
- Colorado Blood Cancer Institute, Denver, Colorado, United States
- University of Miami, Miami, Florida, United States
- AdventHealth Medical Group Blood & Marrow Transplant at Orlando, Orlando, Florida, United States
- Blood & Marrow Transplant Group of Georgia, Atlanta, Georgia, United States
- Augusta University/Georgia Cancer Center, Augusta, Georgia, United States
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States
- University of Kentucky, Lexington, Kentucky, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Regional Cancer Care Associates - Hackensack, Hackensack, New Jersey, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05332054 on ClinicalTrials.govOther trials for Acute myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07493538MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesMasonic Cancer Center, University of Minnesota
- RECRUITINGPHASE2NCT07392242A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid LeukemiaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE3NCT07075016Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyStichting Hemato-Oncologie voor Volwassenen Nederland
- RECRUITINGPHASE1NCT06649227Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19University Hospital, Lille
- RECRUITINGNANCT07237230Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid LeukemiaDonghua Zhang
- RECRUITINGPHASE1, PHASE2NCT06969430A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)Debiopharm International SA
- RECRUITINGNCT06899581Gut Health in Children With CancerGreat Ormond Street Hospital for Children NHS Foundation Trust
- RECRUITINGPHASE2NCT06783790Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, China